Parasitic infectious disease

This early-stage trial is testing a new malaria vaccine candidate, called Pfs48/45, in healthy adults aged 18 to 45 in the UK. The vaccine is designed to block the malaria parasite from spreading, and it's given with an adjuvant called Matrix-M to boost the immune response. The s…

This early-stage trial tested a new vaccine against Plasmodium vivax malaria, given with an adjuvant to boost immune response. It involved 25 healthy adults in the UK to check safety and immune reactions. The study was terminated early, so full results are not available.

This study tested a new, easy-to-dissolve malaria tablet in infants and newborns weighing less than 5 kg who had uncomplicated malaria. The goal was to see how the medicine worked in the body, how safe it was, and how well it treated the infection. The trial was stopped early aft…

This study tested a new pill combining two drugs (albendazole and ivermectin) to treat several types of intestinal worms in children and young adults aged 5 to 18. The goal was to see if the combination worked better than the standard single drug. However, the trial was terminate…

This was a first-in-human study to check the safety and how the body processes a single dose of GSK3494245, a potential treatment for leishmaniasis. It involved 59 healthy adults who received up to three increasing doses of the drug or a placebo. The study was terminated early, s…